Prevention and Treatment of Atherosclerosis: A Practitioner's Guide for 2008

被引:65
作者
Lewis, Sandra J. [1 ,2 ]
机构
[1] Legacy Good Samaritan Hosp, NW Cardiovasc Inst, Div Cardiac Rehabil, Portland, OR 97210 USA
[2] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA
关键词
Atherosclerosis; Hypercholesterolemia; Risk factor; Statin; Treatment; LOW-DENSITY-LIPOPROTEIN; CARDIOVASCULAR-DISEASE; HIGH-RISK; RANDOMIZED-TRIALS; WOMENS HEALTH; STATIN SAFETY; EFFICACY; ROSUVASTATIN; ATORVASTATIN; EVENTS;
D O I
10.1016/j.amjmed.2008.10.016
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Atherosclerosis causes nearly 75% of cardiovascular-related deaths and is found in 80% to 90% of adults >= 30 years old in the United States. Successful treatment minimizes lifetime chances of cardiovascular events, morbidity, and mortality. Risk factors for atherosclerosis should be monitored, beginning in childhood, even in asymptomatic patients. Modifiable factors (e.g., blood pressure, smoking, serum lipids) and nonmodifiable factors (e.g., age, family history) are important in the overall assessment. Clinicians and patients can partner to produce an individualized treatment plan by choosing from a variety of standard approaches. In some patients, improved dietary choices, increased exercise, and smoking cessation will reduce risk to an acceptable degree. To lower risk further, lipid-lowering pharmacotherapy and antihypertensive medication may be combined with these lifestyle improvements. For most of these patients, reducing low-density lipoprotein cholesterol is the most important lipid-lowering goal, and it is best achieved with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin). Some patients may benefit from adjunctive therapies that have proven effects (e.g., niacin, fibrates, plant stanols/sterols, omega-3 fatty acids). Antihypertensive regimens may involve stepwise adjustments of multiple medications. Good clinical judgment and communication of expectations and goals are critical for effective management of atherosclerosis. (c) 2009 Published by Elsevier Inc. The American Journal of Medicine (2009) 122, S38-S50
引用
收藏
页码:S38 / S50
页数:13
相关论文
共 53 条
[1]
Ali Robin, 2007, Am J Geriatr Pharmacother, V5, P52, DOI 10.1016/j.amjopharm.2007.03.008
[2]
*AM AC PED, 1992, PEDIATRICS, V89, P525
[3]
Standards of medical care in diabetes 2008 [J].
不详 .
DIABETES CARE, 2008, 31 :S12-S54
[4]
[Anonymous], 2004, NIH PUBLICATION
[5]
[Anonymous], 2005, HEART DIS STROKE STA
[6]
*ASTRAZENECA PHARM, 2007, CREST PRESCR INF
[7]
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[8]
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (Results from the EXPLORER study) [J].
Ballantyne, Christie M. ;
Weiss, Robert ;
Moccetti, Tiziano ;
Vogt, Anja ;
Eber, Bernd ;
Sosef, Froukje ;
Duffield, Emma .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (05) :673-680
[9]
"Sick Fat," Metabolic Disease, and Atherosclerosis [J].
Bays, Harold E. .
AMERICAN JOURNAL OF MEDICINE, 2009, 122 (01) :S26-S37
[10]
Preventive cardiology and its potential influence on the early natural history of adult heart diseases: The Bogalusa Heart Study and the Heart Smart Program [J].
Berenson, GS ;
Pickoff, AS .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1995, 310 :S133-S138